Obesity Clinical Trials in Las Vegas, Nevada

16 studies are recruiting for obesity in Las Vegas, Nevada right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

   Obesity is a condition where a person has excessive body fat, defined by a body mass index (BMI) of 30 kg/m2 or higher. The goal of this study is to evaluate the effect of various doses of ABBV-295 compared to placebo on reducing body weight at Week 32 in participants with obesity or overweight wit…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Vector Clinical Trials /ID# 282265, Las Vegas, Nevada

   Locations

   64 in total

   Run by

   AbbVie

   See if you can join NCT07752979 on ClinicalTrials.gov

2. A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

   This is randomized, double-blind, placebo-controlled study of the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participants living with overweight or obesity and T2DM. Participants will be randomized to aleniglipron or placebo for a total of 76 weeks of treatmen…

   Stage

   Phase 3

   Ages

   18 to 79

   Site

   ACCOMPLISH-2 Research Site, Las Vegas, Nevada

   Locations

   74 in total

   Run by

   Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

   See if you can join NCT07654374 on ClinicalTrials.gov

3. A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

   The purpose of the studies is to evaluate the efficacy and safety of eloralintide in participants with moderate-to-severe obstructive sleep apnea and obesity or overweight. YDAO is a master protocol designed to support two independent studies: YSA1 and YSA2. Study YSA1 will include participants who…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Palm Research Center Tenaya, Las Vegas, Nevada

   Locations

   115 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07369011 on ClinicalTrials.gov

4. A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

   The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes. Participation will …

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Las Vegas Medical Research, Las Vegas, Nevada

   Locations

   40 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07589608 on ClinicalTrials.gov

5. A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event

   The purpose of this study is to measure the change in high-sensitivity C-reactive protein (hsCRP), a marker of inflammation in the body, with clazakizumab compared with placebo in adults who have elevated hsCRP and at increased risk for cardiovascular event. Participation in the study will last abo…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Excel Clinical Research, LLC, Las Vegas, Nevada

   Locations

   46 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07783802 on ClinicalTrials.gov

6. A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

   The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entry criteria for newl…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Las Vegas Medical Research, Las Vegas, Nevada

   Locations

   57 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06143956 on ClinicalTrials.gov

7. Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

   The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity and type 2 diabetes mellitus. Trial 20210182 is extension of trial 20210184 (NCT06858878).

   Stage

   Phase 3

   Ages

   18 to 99

   Site

   Palm Research Center Inc, Las Vegas, Nevada

   Locations

   45 in total

   Run by

   Amgen

   See if you can join NCT07684144 on ClinicalTrials.gov

8. Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

   The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity or overweight. Trial 20250197 is an extension of trial 20210181 (NCT06858839).

   Stage

   Phase 3

   Ages

   18 to 99

   Site

   Vector Clinical Trials, Las Vegas, Nevada

   Locations

   92 in total

   Run by

   Amgen

   See if you can join NCT07684235 on ClinicalTrials.gov

9. AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight

   The purpose of this clinical study is to find out if zenagamtide is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as oral tablets once a day. Participants will either get zenagamtide (the treatment being tested) or Placebo (trea…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Palm Research Center Inc., Las Vegas, Nevada

   Locations

   41 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07720271 on ClinicalTrials.gov

10. A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

    The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase. Participation in the main phase of the study will last about 75 weeks. Participants w…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    AMR Clinical, Las Vegas, Nevada

    Locations

    158 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT07321886 on ClinicalTrials.gov

11. A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

    Study ASC30-302 (AURORA-2) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesity or overweight and…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    AURORA-2 Clinical Site, Las Vegas, Nevada

    Locations

    135 in total

    Run by

    Ascletis Pharma (China) Co., Limited

    See if you can join NCT07743450 on ClinicalTrials.gov

12. A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

    Study ASC30-301 (AURORA-1) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesity or overweight wit…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    AURORA-1 Clinical Site, Las Vegas, Nevada

    Locations

    122 in total

    Run by

    Ascletis Pharma (China) Co., Limited

    See if you can join NCT07743463 on ClinicalTrials.gov

13. Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

    The purpose of this study is to see how oral semaglutide, when taken in lower doses help lowering of body weight in participants with excess body weight when compared to 'dummy' tablets (placebo). Results from this study will help select the most optimal lower dose of oral semaglutide that can be u…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Jubilee Clinical Research, Inc., Las Vegas, Nevada

    Locations

    62 in total

    Run by

    Novo Nordisk A/S

    See if you can join NCT07770841 on ClinicalTrials.gov

14. A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

    This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to f…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Palm Research Center Inc-Vegas, Las Vegas, Nevada

    Locations

    838 in total

    Run by

    Novo Nordisk A/S

    See if you can join NCT07567001 on ClinicalTrials.gov

15. Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

    Study GSBR-1290-12 is a Phase 3 pivotal, multicenter, global, randomized, placebo-controlled, double-blind study to investigate the long-term efficacy, safety, and tolerability of 3 maintenance doses of aleniglipron once daily (QD) compared with placebo, when used in combination with a reduced-calo…

    Stage

    Phase 3

    Ages

    18 to 79

    Site

    ACCOMPLISH-1 Research Site, Las Vegas, Nevada

    Locations

    71 in total

    Run by

    Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

    See if you can join NCT07654361 on ClinicalTrials.gov

16. A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

    The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and knee osteoarthritis. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the …

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Jubilee Clinical Research, Inc., Las Vegas, Nevada

    Locations

    82 in total

    Run by

    Novo Nordisk A/S

    See if you can join NCT07481630 on ClinicalTrials.gov